Skip to main content

Table 5 Indications for initial low-dose ICS controller therapy in children aged 5 years and below

From: The use of inhaled corticosteroids in pediatric asthma: update

Indication to start low-dose ICS:

Symptom pattern consistent with asthma (Box 1) and asthma symptoms not well-controlled (Box 2), or at least 3 exacerbations per year

OR

Symptom pattern not consistent with asthma, but wheezing episodes occur frequently (e.g. every 6–8 weekly)

BOX 1: Features suggesting a diagnosis of asthma in children 5 years and younger

Feature

Characteristics suggesting asthma

Cough

Recurrent or persistent non-productive cough that may be worse at night or accompanied by some wheezing and breathing difficulties

Cough occurring with exercise, laughing, crying or exposure to tobacco smoke in the absence of an apparent respiratory infection

Wheezing

Recurrent wheezing, including sleep or with triggers such as activity, laughing, crying or exposure to tobacco smoke or air pollution

Difficult or heavy breathing or shortness of breath

Occurring with exercise, laughing or crying

Reduced activity

Not running, playing or laughing at the same intensity as other children; tires earlier during walks (wants to be carried)

Past or family history

Other allergic disease (atopic dermatitis or allergic rhinitis)

Asthma in first-degree relatives

Therapeutic trial with low dose ICS and as-needed SABA

Clinical improvement during 2–3 months of controller treatment and worsening when treatment is stopped

BOX 2: GINA assessment of asthma control in children 5 years and younger

Symptoms in the last 4 weeks

Level of control

Well controlled

Partly controlled

Uncontrolled

Daytime asthma symptoms for more than a few minutes, more than once a week

None

1–2 of these

3–4 of these

Any activity limitation due to asthma (Runs/plays less than other children, tires easily when walking/playing)

Reliever medication (excludes reliever taken before exercise) needed more than once a week

Any night waking or night coughing due to asthma

  1. Legend:
  2. SABA short acting beta2-agonist
  3. Evidence A – data from randomized controlled trials and meta-analyses, rich body of data
  4. Evidence B – data from randomized controlled trials and meta-analyses, limited data
  5. Evidence C – data from nonrandomized trials/observational studies
  6. Evidence D – panel consensus judgment
  7. modified from GINA 2015 [3]